# A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

> **NCT03841448** · PHASE2 · TERMINATED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- IgA Nephropathy (IgAN)
- Berger Disease
- Glomerulonephritis, IgA

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cemdisiran

## Key facts

- **NCT ID:** NCT03841448
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-30
- **Primary completion:** 2022-03-17
- **Final completion:** 2023-06-27
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study was terminated early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period\&were in OLE period. Sponsor had no concerns with safety\&integrity of participants.
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03841448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03841448, "A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03841448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*